CIK 0001348362
- Non-accelerated filer
- Smaller reporting company
Lexaria Bioscience Corp.
Sign in to watch- Ticker
- LEXX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Aug 31
- Incorporated
- NV
- Entity type
- Operating
- EIN
- 202000871
- Phone
- +1 250-765-6424
- Business address
- 100 - 740 MCCURDY ROAD, KELOWNA, British Columbia, Canada, V1X 2P7
- Former names
- Lexaria Corp., LEXARIA CORP.
- 4 Grant or award Director acquired 114,286 shares (grant or award)
- 4 Grant or award President acquired 252,000 shares (grant or award)
- 4 Open-market buy CEO bought 20,000 shares at an average $0.13 ($2,515)
- 4 Open-market buy CEO bought 2,500 shares at $0.15 ($363)
- 4 Open-market buy CEO bought 5,100 shares at $0.13 ($653)
- 4 Open-market buy CEO bought 27,637 shares at an average $0.13 ($3,545)
- 4 Open-market buy CEO bought 19,800 shares at an average $0.13 ($2,494)
- 4 Open-market buy CEO bought 13,340 shares at an average $0.13 ($1,774)
- 4 Open-market buy CEO bought 10,000 shares at $0.15 ($1,500)
- 4 Open-market buy CEO bought 450,000 shares at $0.06 ($27,000)
- 4 Open-market buy CEO bought 5,000 shares at $0.13 ($645)
- 4 Open-market buy CEO bought 24,083 shares at an average $0.12 ($2,910)
- 4 Open-market buy CEO bought 7,500 shares at an average $0.12 ($932)
- 4 Open-market buy CEO bought 7,000 shares at $0.14 ($952)
- 4 Open-market buy CEO bought 62,305 shares at an average $0.12 ($7,445)
- 4 Open-market buy CEO bought 12,000 shares at an average $0.11 ($1,360)
- 4 Open-market buy CEO bought 59,000 shares at an average $0.09 ($5,485)
- 4 Open-market buy President bought 210,000 shares at $0.10 ($21,000)
- 4 Insider Changes in Ownership
- 4 Open-market buy President bought 17,000 shares at an average $0.10 ($1,650)
Page 8 of 21 · 420 filings